サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747709

インシリコ創薬の世界市場

In-Silico Drug Discovery

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
インシリコ創薬の世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インシリコ創薬の世界市場は2030年までに60億米ドルに到達

2024年に33億米ドルと推定されるインシリコ創薬の世界市場は、2024年から2030年にかけてCAGR 10.3%で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるサービスとしてのソフトウェアは、CAGR 11.2%を記録し、分析期間終了時には36億米ドルに達すると予測されます。サービスとしてのコンサルタント事業の成長率は、分析期間中CAGR 9.4%と推定されます。

米国市場は8億7,160万米ドルと推定、中国はCAGR9.9％で成長予測

米国のインシリコ創薬市場は、2024年に8億7,160万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.9%で推移し、2030年には予測市場規模9億4,570万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.5％と8.7％と予測されています。欧州では、ドイツがCAGR約8.2%で成長すると予測されています。

世界のインシリコ創薬市場- 主要動向と促進要因のまとめ

インシリコ創薬が医薬品研究開発パイプラインに革命をもたらす理由とは？

インシリコ創薬とは、計算モデリングとシミュレーション技術を使用して、物理的な実験の前に医薬品候補を特定、最適化、検証することを指します。このアプローチは、仮説の創出、ターゲットの検証、リード化合物のスクリーニング、毒性予測をすべてバーチャルな環境でより迅速に行うことを可能にし、従来の医薬品開発を根本的に変革しています。従来のウェットラボの手法とは対照的に、インシリコ技術は、研究者が迅速かつコスト効率よく広大な化学的・生物学的空間を探索することを可能にし、医薬品研究開発の初期段階を大幅に加速します。

これらのプラットフォームは、分子ドッキング、ファーマコフォアモデリング、定量的構造活性相関（QSAR）、機械学習アルゴリズムなどの多様なツールを活用し、薬物と標的の相互作用をシミュレーションし、化合物の有効性を予測します。研究開発コストの上昇と臨床試験での高い離脱率を背景に、候補化合物選択のリスクを軽減し、開発スケジュールを合理化するインシリコ手法の能力が、バイオテクノロジー企業、学術機関、製薬企業での採用拡大を後押ししています。インシリコアプローチは、精密医療や既存薬の再利用においても重要な役割を果たしており、競合情勢における戦略的価値をさらに高めています。

インシリコ法の範囲と精度を拡大する技術的進歩とは？

インシリコ創薬の状況は、計算能力、アルゴリズムの高度化、データ統合の飛躍的進歩によって急速に進化しています。人工知能とディープラーニングの進歩は、標的同定、化合物スクリーニング、ADMET（吸収、分布、代謝、排泄、毒性）プロファイリングにおいて、より精度の高い予測モデルを可能にしています。大規模な生化学データセットで訓練されたニューラルネットワークは、複雑な構造-機能関係を推論し、薬理学的特性が向上した新規化合物の構造を提案できるようになりました。

クラウドベースのコンピューティングとハイパフォーマンス・コンピューティング（HPC）プラットフォームにより、大規模な分子シミュレーション、仮想スクリーニング、マルチターゲット最適化をリアルタイムで実行することが可能になっています。バイオインフォマティクスとケモインフォマティクス・プラットフォームの統合により、研究者はインシリコ・フレームワークの中で、ゲノミクス、プロテオミクス、トランスクリプトミクスといったマルチオミクスデータを解析し、より多くの情報に基づいた標的探索を行えるようになっています。さらに、デジタルツインモデルやシステム生物学モデルの出現により、研究者はインシリコで疾患進行や薬物反応をシミュレーションできるようになり、仮説検証や個別化治療戦略のための強力なツールを提供しています。

インシリコ・プラットフォームの採用をリードしている治療分野と組織は？

インシリコ創薬の導入は、腫瘍学、神経学、希少疾患、感染症などの複雑で高コストの治療領域をターゲットとする製薬企業によって主導されています。これらの領域では、高精度ターゲティング、バイオマーカー探索、作用機序解明などのニーズが高いため、計算機的アプローチから大きな恩恵を受けています。例えば腫瘍学では、腫瘍特異的相互作用を予測することにより、キナーゼ阻害剤や免疫療法を設計するためにインシリコツールが使用されています。神経変性研究では、シミュレーションが血液脳関門のモデル化や中枢神経系透過性化合物の同定に役立っています。

学術研究機関やバイオベンチャー企業も、ソフトウェアプロバイダーやデータサイエンス企業との連携を通じて、インシリコツールの利用を進める上で大きな役割を果たしています。オープンソースの分子データベースやAI対応プラットフォームに焦点を当てた官民パートナーシップやコンソーシアムが、急速なイノベーションと技術の民主化を支えています。医薬品開発業務受託機関（CRO）は、時間効率とコスト効率の高いソリューションを求める顧客の需要の高まりに応えるため、創薬サービスにインシリコサービスを組み込む動きが加速しています。さらに、規制当局もシミュレーションベースの前臨床データに寛容になってきており、主流の医薬品開発におけるインシリコアプローチの役割がさらに正当化されつつあります。

インシリコ創薬市場の成長はいくつかの要因によってもたらされる...

インシリコ創薬市場の成長には、医薬品開発コストの高騰、研究開発の複雑化、イノベーションサイクルの迅速化といった要因があります。従来の研究室や臨床のワークフローが非効率性を増す中、製薬業界は初期段階の開発を加速し、動物実験への依存を減らし、成功確率の高い候補化合物を優先するために、インシリコ・プラットフォームに注目しています。ゲノム配列決定、電子カルテ、化合物ライブラリーのキュレーションに支えられた生物医学ビッグデータの急増は、ますます正確でスケーラブルな計算モデルの燃料となっています。

ヘルスケアにおける精密医療とAIの統合を支援する政策と資金提供のイニシアティブも、市場成長の触媒となっています。特に新興の疾患や公衆衛生の危機に対応するため、データ主導型の研究へと世界的にシフトしていることから、治療薬の迅速なスクリーニングと再利用におけるシミュレーションツールの戦略的価値が浮き彫りになっています。これに伴い、ベンチャーキャピタル、製薬企業との提携、政府プログラムからの投資が増加し、プラットフォームの革新、新興企業の開発、人材獲得が支援されています。俊敏でインテリジェント、かつ予測的な創薬フレームワークへの需要が高まる中、インシリコ手法は将来の医薬品イノベーションの基盤となることが期待されています。

セグメント

タイプ（サービスとしてのソフトウェア、サービスとしてのコンサルタント、ソフトウェア）;エンドユーザー（契約研究機関、製薬、学術・研究機関、その他のエンドユーザー）

調査対象企業の例（全34件）

  • Abzena Ltd.
  • Aitia
  • Antiverse
  • Atomwise, Inc.
  • BenevolentAI
  • BioNTech SE
  • BioSymetrics Inc.
  • Certara, USA
  • Chemical Computing Group ULC
  • Clarivate
  • Curia Global Inc.
  • Dassault Systemes SE
  • DenovAI
  • Exscientia
  • GenScript
  • Iktos
  • Insilico Medicine
  • Insitro
  • Isomorphic Labs
  • Ligand Pharmaceuticals

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35237

Global In-Silico Drug Discovery Market to Reach US$6.0 Billion by 2030

The global market for In-Silico Drug Discovery estimated at US$3.3 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Software as a Service, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Consultancy as a Service segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$871.6 Million While China is Forecast to Grow at 9.9% CAGR

The In-Silico Drug Discovery market in the U.S. is estimated at US$871.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$945.7 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global In-Silico Drug Discovery Market - Key Trends & Drivers Summarized

Why Is In-Silico Drug Discovery Revolutionizing Pharmaceutical R&D Pipelines?

In-silico drug discovery refers to the use of computational modeling and simulation technologies to identify, optimize, and validate drug candidates before physical experimentation. This approach is fundamentally transforming traditional drug development by enabling faster hypothesis generation, target validation, lead compound screening, and toxicity prediction-all within a virtual environment. In contrast to conventional wet-lab methods, in-silico techniques allow researchers to explore vast chemical and biological spaces quickly and cost-effectively, significantly accelerating the early stages of pharmaceutical R&D.

These platforms harness diverse tools such as molecular docking, pharmacophore modeling, quantitative structure-activity relationships (QSAR), and machine learning algorithms to simulate drug-target interactions and predict compound efficacy. With rising R&D costs and high attrition rates in clinical trials, the ability of in-silico methods to de-risk candidate selection and streamline development timelines is driving their growing adoption across biotech firms, academic institutions, and pharmaceutical companies. In-silico approaches also play a critical role in precision medicine and repurposing of existing drugs, further broadening their strategic value in a competitive innovation landscape.

What Technological Advancements Are Expanding the Scope and Accuracy of In-Silico Methods?

The in-silico drug discovery landscape is rapidly evolving with breakthroughs in computational power, algorithmic sophistication, and data integration. Advances in artificial intelligence and deep learning are enabling predictive models with higher accuracy in target identification, compound screening, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. Neural networks trained on large biochemical datasets can now infer complex structure-function relationships and suggest novel compound structures with enhanced pharmacological properties.

Cloud-based computing and high-performance computing (HPC) platforms are making it possible to perform large-scale molecular simulations, virtual screening, and multi-target optimization in real time. Integration of bioinformatics and chemoinformatics platforms is allowing researchers to analyze multi-omic data-genomics, proteomics, transcriptomics-within in-silico frameworks for more informed target discovery. Additionally, the emergence of digital twins and systems biology models is enabling researchers to simulate disease progression and drug response in silico, offering powerful tools for hypothesis testing and personalized treatment strategies.

Which Therapeutic Areas and Organizations Are Leading Adoption of In-Silico Platforms?

Adoption of in-silico drug discovery is being led by pharmaceutical companies targeting complex and high-cost therapeutic areas such as oncology, neurology, rare diseases, and infectious diseases. These domains benefit significantly from computational approaches due to the high need for precision targeting, biomarker discovery, and mechanism-of-action understanding. In oncology, for instance, in-silico tools are used to design kinase inhibitors or immunotherapies by predicting tumor-specific interactions. In neurodegenerative research, simulations help model the blood-brain barrier and identify CNS-penetrant compounds.

Academic research institutions and biotech startups are also playing a major role in advancing the use of in-silico tools, often through collaborations with software providers and data science companies. Public-private partnerships and consortiums focused on open-source molecular databases and AI-enabled platforms are supporting rapid innovation and technology democratization. Contract research organizations (CROs) are increasingly integrating in-silico services into their drug discovery offerings to meet growing client demand for time-efficient and cost-effective solutions. Furthermore, regulatory bodies are showing increasing openness to simulation-based preclinical data, further legitimizing the role of in-silico approaches in mainstream drug development.

The Growth in the In-Silico Drug Discovery Market Is Driven by Several Factors…

The growth in the in-silico drug discovery market is driven by several factors including escalating drug development costs, increased R&D complexity, and the urgent need for faster innovation cycles. As traditional laboratory and clinical workflows face growing inefficiencies, the pharmaceutical industry is turning to in-silico platforms to accelerate early-stage development, reduce dependency on animal testing, and prioritize candidates with higher success probabilities. The proliferation of biomedical big data, supported by genomic sequencing, electronic health records, and curated compound libraries, is providing the fuel for increasingly accurate and scalable computational models.

Policy and funding initiatives supporting precision medicine and AI integration in healthcare are also catalyzing market growth. The global shift toward data-driven research, especially in response to emerging diseases and public health crises, has underscored the strategic value of simulation tools in rapidly screening and repurposing therapeutics. In tandem, growing investment from venture capital, pharmaceutical alliances, and government programs is supporting platform innovation, start-up development, and talent acquisition. As demand for agile, intelligent, and predictive drug discovery frameworks rises, in-silico methods are expected to become foundational to the future of pharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the In-Silico Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Software as a Service, Consultancy as a Service, Software); End-Use (Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Abzena Ltd.
  • Aitia
  • Antiverse
  • Atomwise, Inc.
  • BenevolentAI
  • BioNTech SE
  • BioSymetrics Inc.
  • Certara, USA
  • Chemical Computing Group ULC
  • Clarivate
  • Curia Global Inc.
  • Dassault Systemes SE
  • DenovAI
  • Exscientia
  • GenScript
  • Iktos
  • Insilico Medicine
  • Insitro
  • Isomorphic Labs
  • Ligand Pharmaceuticals

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • In-Silico Drug Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Costs and Long Development Timelines Propel Adoption of In-Silico Drug Discovery for Faster, Cost-Efficient Candidate Screening
    • Advancements in AI, Machine Learning, and Deep Learning Algorithms Enhance Predictive Accuracy of Molecular Modeling and Docking
    • Integration of High-Throughput Virtual Screening (HTVS) Accelerates Identification of Promising Drug Candidates at Scale
    • Growth in Cloud Computing and GPU Acceleration Supports Real-Time Simulation and Complex In-Silico Workflows
    • Pharmaceutical Shift Toward Precision and Personalized Medicine Strengthens Business Case for Computationally Driven Drug Design
    • Expansion of Multi-Omics Data Repositories Throws the Spotlight on Data-Driven Insights for Target Validation and Biomarker Discovery
    • Adoption of Digital Twins and Virtual Human Models Enhances Simulation of Drug Efficacy, Toxicity, and Metabolism
    • Increasing Use of In-Silico Tools in Rare Disease and Orphan Drug Development Creates Opportunities in Niche Therapeutic Areas
    • Regulatory Acceptance of In-Silico Evidence for IND and NDA Filings Supports Broader Adoption in Preclinical Research
    • Integration With Laboratory Information Management Systems (LIMS) and ELNs Enables Seamless End-to-End Drug Discovery Pipelines
    • Rising Use of Quantum Computing in Early-Stage Drug Discovery Unlocks Potential for Ultra-Fast Molecular Property Predictions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World In-Silico Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for In-Silico Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Software as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Software as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Consultancy as a Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Consultancy as a Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for In-Silico Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for In-Silico Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • In-Silico Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for In-Silico Drug Discovery by Type - Software as a Service, Consultancy as a Service and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for In-Silico Drug Discovery by Type - Percentage Breakdown of Value Sales for Software as a Service, Consultancy as a Service and Software for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for In-Silico Drug Discovery by End-Use - Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for In-Silico Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Contract Research Organizations, Pharmaceuticals, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION